Ads
related to: 2022 fda new drug approvals 2023- Recommended Dosing
Determine The Appropriate Dosing
For A Patient On IMFINZI.
- Clinical Study Results
View Clinical Study Results
& Efficacy Info For IMFINZI.
- Request Representative
Fill Out A Brief Form To Request
Assistance From A Representative.
- Safety Information
Learn About Safety & Efficacy
Information For IMFINZI.
- Recommended Dosing
Search results
Results From The WOW.Com Content Network
Mavacamten was approved for medical use in the United States in April 2022. [ 8 ] [ 12 ] [ 13 ] [ 14 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication . [ 15 ] [ 16 ]
Mosunetuzumab was approved for medical use in the European Union in June 2022, [4] and in the United States in December 2022. [ 3 ] [ 7 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication .
Nedosiran was approved for medical use in the United States in September 2023. [ 1 ] [ 4 ] [ 5 ] [ 3 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication . [ 6 ]
A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...
The new drug is an alternative to opioids, which, even if used short-term, can lead to addiction and at times, overdose, according to the Mayo Clinic. In 2022, more than 81,000 people died from an ...
Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...
In addition to those highlights, Pfizer also nabbed Food and Drug Administration (FDA) approvals for two other infectious disease therapies: TicoVac, a pioneering vaccine for tick-borne ...
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...